Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Leading cancer researcher, Dr. Lewis Cantley, named a winner of the inaugural Breakthrough Prize in Life Sciences

Dr. Lewis Cantley, a leading cancer researcher credited with discovering a family of enzymes fundamental to understanding cancer, was named a winner of the inaugural Breakthrough Prize in Life Sciences, the world’s richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life.

22 Feb 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

Imatinib can relieve and slow down progression of multiple sclerosis

A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Benaroya Research Institute establishes T1D Exchange Biobank Operations Center

In a major effort to advance discoveries in type 1 diabetes research, the Benaroya Research Institute at Virginia Mason (BRI) established the T1D Exchange Biobank Operations Center with a $4.4 million grant from The Leona M. and Harry B. Helmsley Charitable Trust.

15 Feb 2013

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

March is National Autoimmune Disease Awareness Month 2013. To mark the annual event, the American Autoimmune Related Diseases Association Inc. (AARDA) is encouraging the national and local media around the country to report stories on autoimmune diseases (AD) and autoimmunity as a category of disease.

13 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Scientists identify specific cellular events that appear key to lupus

A team led by scientists at The Scripps Research Institute (TSRI) has identified specific cellular events that appear key to lupus, a debilitating autoimmune disease that afflicts tens of millions of people worldwide. The findings suggest that blocking this pathway in lupus-triggering cells could be a potent weapon against the disease.

5 Feb 2013

Adequate vitamin D levels during young adulthood may reduce risk of type 1 diabetes

Having adequate levels of vitamin D during young adulthood may reduce the risk of adult-onset type 1 diabetes by as much as 50%, according to researchers at Harvard School of Public Health (HSPH).

5 Feb 2013

Immunosuppressive drugs do not increase risk of cancer in lupus patients

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC).

28 Jan 2013

Study sheds new light on why certain people are more likely to suffer from RA

University of Michigan research sheds new light on why certain people are more likely to suffer from rheumatoid arthritis - paving the way to explore new treatments for both arthritis and other autoimmune diseases.

28 Jan 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

BH3-mimetics might be new option for treatment of autoimmune conditions

Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.

23 Jan 2013

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an immune attack against viruses, cancerous tumors and other damaged or infected cells.

21 Jan 2013

Researchers identify clear role for tags in mediating genetic risk for rheumatoid arthritis

In one of the first genome-wide studies to hunt for both genes and their regulatory "tags" in patients suffering from a common disease, researchers have found a clear role for the tags in mediating genetic risk for rheumatoid arthritis (RA), an immune disorder that afflicts an estimated 1.5 million American adults.

21 Jan 2013

RSAS honors Feinstein Institute scientist with Crafoord Prize for genetic research on arthritis

The Royal Swedish Academy of Sciences announced today that Peter K. Gregersen , MD, a scientist at The Feinstein Institute for Medical Research, will receive the prestigious Crafoord Prize for his genetic research in the area rheumatoid arthritis.

18 Jan 2013

Autoimmune Disease News and Research

Further Reading

Leading cancer researcher, Dr. Lewis Cantley, named a winner of the inaugural Breakthrough Prize in Life Sciences

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Imatinib can relieve and slow down progression of multiple sclerosis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

Benaroya Research Institute establishes T1D Exchange Biobank Operations Center

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

Infusions of regulatory T cells turn off autoimmune attack on joints

Scientists identify specific cellular events that appear key to lupus

Adequate vitamin D levels during young adulthood may reduce risk of type 1 diabetes

Immunosuppressive drugs do not increase risk of cancer in lupus patients

Study sheds new light on why certain people are more likely to suffer from RA

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

New hope for lupus patients

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

BH3-mimetics might be new option for treatment of autoimmune conditions

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

Researchers identify clear role for tags in mediating genetic risk for rheumatoid arthritis

RSAS honors Feinstein Institute scientist with Crafoord Prize for genetic research on arthritis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News